INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVANEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (
NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance BiotherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVANEW ORLEANS, June 04, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
IOVANCE BIOTHERAPEUTICS DEADLINE IS JULY 14, 2025 - Investors are Encouraged to Contact Kaplan FoxSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
IOVANCE BIOTHERAPEUTICS DEADLINE IS JULY 14, 2025 - Investors are Encouraged to Contact Kaplan FoxNEW YORK, NY - June 4, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (
NASDAQ: IOVA) on behalf of investors that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025 (the “Class Period”).
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVANEW YORK and NEW ORLEANS, June 03, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Compass Diversified, Digimarc, Elevance Health, and Iovance and Encourages Investors to Contact the FirmNEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Compass Diversified (
NYSE:CODI), Digimarc Corporation (
NASDAQ:DMRC), Elevance Health, Inc. (
NYSE:ELV), and Iovance Biotherapeutics, Inc. (
NASDAQ:IOVA). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVANEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (
NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVANEW ORLEANS, May 28, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
IOVA Investors Have the Opportunity to Lead the Iovance Securities Fraud Lawsuit with Faruqi & Faruqi, LLPFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVANEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (
NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVANEW YORK CITY and NEW ORLEANS, May 27, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Kaplan Fox Alerts Investors of Iovance Biotherapeutics, Inc. (IOVA) to the Lead Plaintiff Deadline on July 14, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Alerts Investors of Iovance Biotherapeutics, Inc. (IOVA) to the Lead Plaintiff Deadline on July 14, 2025NEW YORK, NY - May 24, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (
NASDAQ: IOVA) on behalf of investors that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025 (the “Class Period”).
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLPFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVANEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (
NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVANEW ORLEANS, May 21, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or “the Company”) (
NASDAQ: IOVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
